SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
Hospital Ramón y Cajal
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (8)
2024
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment
2021
-
Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach
Journal of Personalized Medicine, Vol. 11, Núm. 8
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
-
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724
2018
-
Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii91-viii92
-
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824
-
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829
2017
-
Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts
Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657